DROPERIDOL- droperidol injection, solution Hikma Pharmaceuticals USA Inc.

Droperidol Injection, USP

1 mL and 2 mL Vials FOR INTRAVENOUS OR INTRAMUSCULAR USE ONLY Rx only

WARNING

Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses. Some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal.

Due to its potential for serious proarrhythmic effects and death, droperidol should be reserved for use in the treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see **Warnings**, **Adverse Reactions**, **Contraindications**, and **Precautions**).

Cases of QT prolongation and serious arrhythmias (e.g., torsade de pointes) have been reported in patients treated with droperidol. Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, droperidol should <u>NOT</u> be administered. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for arrhythmias.


Droperidol is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome.

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). Other risk factors may include age over 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates. Droperidol should be initiated at a low dose and adjusted upward, with caution, as needed to achieve the desired effect.

DESCRIPTION

Droperidol Injection, USP is a neuroleptic (tranquilizer) agent. Droperidol Injection, USP is

available in vials. Each milliliter contains 2.5 mg of droperidol in an aqueous solution adjusted to pH 3.4 \pm 0.4 with lactic acid. Droperidol is chemically identified as 1-[1-[3-(*p*-fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone with a molecular weight of 379.43. The structural formula of droperidol is:



Molecular formula: C₂₂H₂₂FN₃O₂, partition coefficient in n-octanol: water: 3.46, pKa: 7.46

Droperidol Injection, USP is a sterile, non-pyrogenic, aqueous solution for intravenous or intramuscular injection.

CLINICAL PHARMACOLOGY

Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness.

Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period.

Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.

The onset of action of single intramuscular and intravenous doses is from three to ten minutes following administration, although the peak effect may not be apparent for up to thirty minutes. The duration of the tranquilizing and sedative effects generally is two to four hours, although alteration of alertness may persist for as long as twelve hours.

INDICATIONS AND USAGE

Droperidol Injection, USP is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures.

CONTRAINDICATIONS

Droperidol is contraindicated in patients with known or suspected QT prolongation (i.e., QTc interval greater than 440 msec for males or 450 msec for females). This would include patients with congenital long QT syndrome.

Droperidol is contraindicated in patients with known hypersensitivity to the drug.

Droperidol is not recommended for any use other than for the treatment of perioperative nausea and vomiting in patients for whom other treatments are ineffective or inappropriate (see **WARNINGS**).

WARNINGS

Droperidol should be administered with extreme caution in the presence of risk factors for development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see **PRECAUTIONS**, **Drug Interactions**), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance.

Effects on Cardiac Conduction

A dose-dependent prolongation of the QT interval was observed within 10 minutes of droperidol administration in a study of 40 patients without known cardiac disease who underwent extracranial head and neck surgery. Significant QT prolongation was observed at all three dose levels evaluated, with 0.1, 0.175, and 0.25 mg/kg associated with prolongation of median QTc by 37, 44, and 59 msec, respectively.

Cases of QT prolongation and serious arrhythmias (e.g. torsade de pointes, ventricular arrythmias, cardiac arrest, and death) have been observed during post-marketing treatment with droperidol. Some cases have occurred in patients with no known risk factors and at doses at or below recommended doses. There has been at least one case of nonfatal torsade de pointes confirmed by rechallenge.

Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, droperidol should **NOT** be administered. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for arrhythmias.

FLUIDS AND OTHER COUNTERMEASURES TO MANAGE HYPOTENSION SHOULD BE READILY AVAILABLE.

As with other CNS depressant drugs, patients who have received droperidol should have appropriate surveillance.

It is recommended that opioids, when required, initially be used in reduced doses.

As with other neuroleptic agents, very rare reports of neuroleptic malignant syndrome (altered consciousness, muscle rigidity and autonomic instability) have occurred in patients who have received droperidol. Since it may be difficult to distinguish neuroleptic

malignant syndrome from malignant hyperpyrexia in the perioperative period, prompt treatment with dantrolene should be considered if increases in temperature, heart rate or carbon dioxide production occur.

PRECAUTIONS

General

The initial dose of droperidol should be appropriately reduced in elderly, debilitated and other poor-risk patients. The effect of the initial dose should be considered in determining incremental doses.

Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics, can alter respiration by blocking intercostal nerves and can cause peripheral vasodilatation and hypotension because of sympathetic blockade. Through other mechanisms (see **CLINICAL PHARMACOLOGY**), droperidol can also alter circulation. Therefore, when droperidol is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients elected for these forms of anesthesia.

If hypotension occurs, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy. Repositioning the patient to improve venous return to the heart should be considered when operative conditions permit. It should be noted that in spinal and peridural anesthesia, tilting the patient into a headdown position may result in a higher level of anesthesia than is desirable, as well as impair venous return to the heart. Care should be exercised in moving and positioning of patients because of a possibility of orthostatic hypotension. If volume expansion with fluids plus these other countermeasures do not correct the hypotension, then the administration of pressor agents other than epinephrine should be considered. Epinephrine may paradoxically decrease the blood pressure in patients treated with droperidol due to the alpha-adrenergic blocking action of droperidol.

Since droperidol may decrease pulmonary arterial pressure, this fact should be considered by those who conduct diagnostic or surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient Vital signs and ECG should be monitored routinely.

When the EEG is used for postoperative monitoring, it may be found that the EEG pattern returns to normal slowly.

Impaired Hepatic or Renal Function

Droperidol should be administered with caution to patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs.

Pheochromocytoma

In patients with diagnosed/suspected pheochromocytonia, severe hypertension and tachycardia have been observed after the administration of droperidol.

Drug Interactions

Potentially Arrhythmogenic Agents: Any drug known to have the potential to prolong the QT interval should not be used together with droperidol. Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants.

Caution should be used when patients are taking concomitant drugs known to induce hypokalemia or hypomagnesemia as they may precipitate QT prolongation and interact with droperidol. These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential.

CNS Depressant Drugs: Other CNS depressant drugs (e.g., barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with droperidol. Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No carcinogenicity studies have been carried out with droperidol. The micronucleus test in female rats revealed no mutagenic effects in single oral doses as high as 160 mg/kg. An oral study in rats (Segment I) revealed no impairment of fertility in either male or females at 0.63, 2.5 and 10 mg/kg doses (approximately 2.9 and 36 times maximum recommended human iv/im dosage).

Pregnancy

Droperidol administered intravenously has been shown to cause a slight increase in mortality of the newborn rat at 4.4 times the upper human dose. At 44 times the upper human dose, mortality rate was comparable to that for control animals. Following intramuscular administration, increased mortality of the offspring at 1.8 times the upper human dose is attributed to CNS depression in the dams who neglected to remove placentae from their offspring. Droperidol has not been shown to be teratogenic in animals. There are no adequate and well-controlled studies in pregnant women.

Droperidol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery

There are insufficient data to support the use of droperidol in labor and delivery. Therefore, such use is not recommended.

Nursing Mothers

It is not known whether droperidol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when droperidol is administered to a nursing mother.

Pediatric Use

The safety of droperidol in children younger than two years of age has not been established.

ADVERSE REACTIONS

QT interval prolongation, torsade de pointes, cardiac arrest, and ventricular tachycardia have been reported in patients treated with droperidol. Some of these cases were associated with death. Some cases occurred in patients with no known risk factors, and some were associated with droperidol doses at or below recommended doses.

Physicians should be alert to palpitations, syncope, or other symptoms suggestive of episodes of irregular cardiac rhythm in patients taking droperidol and promptly evaluate such cases (see **WARNINGS**, **Effects on Cardiac Conduction**).

The most common somatic adverse reactions reported to occur with droperidol are mild to moderate hypotension and tachycardia, but these effects usually subside without treatment. If hypotension occurs and is severe or persists, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy.

The most common behavioral adverse effects of droperidol include dysphoria, postoperative drowsiness, restlessness, hyperactivity and anxiety, which can either be the result of an inadequate dosage (lack of adequate treatment effect) or of an adverse drug reaction (part of the symptom complex of akathisia).

Care should be taken to search for extrapyramidal signs and symptoms (dystonia, akathisia, oculogyric crisis) to differentiate these different clinical conditions. When extrapyramidal symptoms are the cause, they can usually be controlled with anticholinergic agents.

Postoperative hallucinatory episodes (sometimes associated with transient periods of mental depression) have also been reported.

Other less common reported adverse reactions include anaphylaxis, dizziness, chills and/or shivering, laryngospasm, and bronchospasm.

Elevated blood pressure, with or without pre-existing hypertension, has been reported following administration of droperidol combined with fentanyl citrate or other parenteral analgesics. This might be due to unexplained alterations in sympathetic activity following large doses: however, it is also frequently attributed to anesthetic or surgical stimulation during light anesthesia.

To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Manifestations: The manifestations of droperidol overdosage are an extension of its pharmacologic actions and may include QT prolongation and serious arrhythmias (e.g., torsade de pointes) (see **BOX WARNING**, **WARNINGS**, and **PRECAUTIONS**).

Treatment: In the presence of hypoventilation or apnea, oxygen should be administered and respiration should be assisted or controlled as indicated. A patent airway must be maintained; an oropharyngeal airway or endotracheal tube might be indicated. The patient should be carefully observed for 24 hours; body warmth and adequate fluid intake should be maintained. If hypotension occurs and is severe or persists, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy (see **PRECAUTIONS**).

If significant extrapyramidal reactions occur in the context of an overdose, an anticholinergic should be administered.

The intravenous Median Lethal Dose of droperidol is 20 to 43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11 to 13 mg/kg in rabbits. The intramuscular Median Lethal Dose of droperidol is 195 mg/kg in mice; 104 to 110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs.

DOSAGE AND ADMINISTRATION

Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical procedure involved.

Vital signs and ECG should be monitored routinely.

Adult dosage: The maximum recommended initial dose of droperidol is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. However, additional doses should be administered with caution, and only if the potential benefit outweighs the potential risk.

Children's dosage: For children two to 12 years of age, the maximum recommended initial dose is 0.1 mg/kg, taking into account the patient's age and other clinical factors. However, additional doses should be administered with caution, and only if the potential benefit outweighs the potential risk.

See **WARNINGS** and **PRECAUTIONS** for use of droperidol with other CNS depressants and in patients with altered response.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If such abnormalities are observed, the drug should not be administered.

HOW SUPPLIED

Droperidol Injection, USP is available as:

NDC 0143-9515-25, 2.5 mg/mL, 1 mL vials in packages of 25

NDC 0143-9514-25, 2.5 mg/mL, 2 mL vials in packages of 25

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

REFERENCES

- 1. Saarnivaara L, Klemola UM, Lindgren L, et al. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anesthesia. Acta Anaesthesiol Scand 1990: 34: 276-81.
- 2. Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by

enflurane, isoflurane, and halothane in humans. Anesth Analg 1991:72:137-44.

- 3. Späth G. Torsade des pointe oder die andere Ursache des plötz-lichen Herztodes. Wien: Ueberreuter, 1998.
- 4. Riley DC, Schmeling WT, Al-Wathiqui MH, et al. Prolongation of the QT-interval by volatile anesthetics in chronically instrumented dogs. Anesth Analg 1988: 67: 741-9.
- 5. McConachie I, Keaveny JP, Healy TF, et al. Effects of anaesthesia on the QT-interval. Br J Anaesth 1989: 63: 558-60.
- 6. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997: 17(3): 531-7.
- 7. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994: 79: 983-6.

Manufactured by:

HIKMA FARMACÊUTICA (PORTUGAL), S.A. Estrada do Rio da Mó, 8, 8A e 8B - Fervença - 2705-906 Terrugem SNT, PORTUGAL

Distributed by:

Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922

PIN412-WES/2

Revised: February 2022

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0143-9515-01 Rx only

Droperidol

Injection, USP

2.5 mg/mL

For IV or IM Use

Protect From Light

1 mL Single Dose Vial



NDC 0143-9515-25 Rx only

Droperidol Injection, USP

2.5 mg/mL

Preservative Free

For Intravenous or

Intramuscular Use

25 x 1 mL Single Dose Vials



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0143-9514-01 Rx only

Droperidol Injection, USP

5 mg per 2 mL

(2.5 mg/mL)

For IV or IM use

Protect From Light

2 mL Single Dose Vial



NDC 0143-9514-25 Rx only Droperidol Injection, USP 5 mg per 2 mL (2.5 mg/mL) Preservative Free For Intravenous or Intramuscular Use

25 x 2 mL Single Dose Vials



DROPERIDO	L							
droperidol injection, solution								
Product Inform	nation							
Product Type		HUMAN PRESCRIPTION DRUG	G Item Code (Source) NDC:0143-951			NDC:0143-9515		
Route of Adminis	stration	INTRAMUSCULAR, INTRAVENOUS						
		Malaha						
Active Ingredient/Active Moiety								
Ingredient Name				Basis of S	strength	Strength		
DROPERIDOL (UNII: 09U0F09D5X) (DROPERIDOL - UNII:09U0F09D5X)				DROPERIDOL		2.5 mg in 1 mL		
Inactive Ingredients								
mactive myret								
Ingredient Name					St	rength		
LACTIC ACID (UNII: 33X04XA5AT)								
WATER (UNII: 059QF0KO0R)								
Packaging								
# Item Code	Pac	kage Description	Ма	rketing Sta Date	rt Ma	arketing End Date		
1 NDC:0143-9515- 25	25 in 1 CARTO	N	06/01/	2022				

Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source Route of Administration INTRAMUSCULAR, INTRAVENOUS	1 NDC:0143-9515- 01 Droduct 1 mL in 1 VIAL; Type 0: Not a Combination Product								
Marketing Category Application Number or Monograph Citation Marketing Start Date ANDA ANDA208197 06/01/2022 ANDA ANDA208197 06/01/2022 DROPERIDOL dotoperidol injection, solution Item Code (Source Route of Administration Product Type HUMAN PRESCRIPTION DRUG Item Code (Source Route of Administration Ingredient/Active Moiety Ingredient Name Basis of Stren DROPERIDOL (UNII: 09U0F09D5X) DROPERIDOL DROPERIDOL Inactive Ingredients Ingredient Name Basis of Stren Inactive Ingredients Ingredient Name DROPERIDOL Packaging Ingredient Name Ingredient Stren Packaging Ingredient Name Ingredient Stren Packaging Ingredient Name Ingredient Stren IndC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination Imactice Ingredient Marketing Information Marketing Application Number or Monograph Marketing Start									
Category Citation Date ANDA ANDA208197 06/01/2022 DROPERIDOL droperidol injection, solution Image: Calegory of the solution Image: Calegory of the solution Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source Route of Administration Route of Administration INTRAMUSCULAR, INTRAVENOUS Image: Calegory of the solution Active Ingredient/Active Moiety Basis of Stren DROPERIDOL (UNII: 09U0F09D5X) (DROPERIDOL - UNII:09U0F09D5X) DROPERIDOL Inactive Ingredients Ingredient Name Basis of Stren Inactive Ingredients Ingredient Name Packaging # Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination Imarketing Information									
Introduct Information Product Information Product Type HUMAN PRESCRIPTION DRUG Route of Administration INTRAMUSCULAR, INTRAVENOUS Active Ingredient/Active Moiety Ingredient Name Basis of Stren DROPERIDOL (UNII: 0900F09D5X) DROPERIDOL Ingredient Name Basis of Stren DROPERIDOL (UNII: 0900F09D5X) DROPERIDOL Ingredient Name WATER (UNII: 0590F0KO0R) LACTIC ACID (UNII: 33X04XA5AT) Imarketing Start Date Packaging # Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 06/01/2022 Imarketing Information Marketing Information	Marketing End Date								
Product Information HUMAN PRESCRIPTION DRUG Item Code (Source Route of Administration INTRAMUSCULAR, INTRAVENOUS Item Code (Source Active Ingredient/Active Moiety Ingredient Name Basis of Stren DROPERIDOL (UNII: 0900F09D5X) (DROPERIDOL - UNII:0900F09D5X) DROPERIDOL Inactive Ingredients Ingredient Name Basis of Stren Inactive Ingredients Ingredient Name Ingredient S Ingredient S Ingredient Name Ingredient S Ingredient S Ingredient S Ingredient S									
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source Route of Administration INTRAMUSCULAR, INTRAVENOUS Intem Code (Source Active Ingredient/Active Moiety Ingredient Name Basis of Stren DROPERIDOL (UNII: 0900F09D5X) (DROPERIDOL - UNII:0900F09D5X) DROPERIDOL Ingredient Name Basis of Stren DROPERIDOL (UNII: 0590F0KOOR) Ingredient Name MATER (UNII: 0590F0KOOR) Ingredient Name Actric Acid (UNII: 33X04XA5AT) Marketing Start Packaging Marketing Information Marketing Application Number or Monograph Marketing Start									
Product Type HUMAN PRESCRIPTION DRUG Lew Code (Source Route of Administration INTRAMUSCULAR, INTRAVENOUS Active Ingredient/Active Moiety Active Ingredient/Active Moiety Basis of Stren DROPERIDOL (UNII: 09U0F09D5X) (DROPERIDOL - UNII:09U0F09D5X) DROPERIDOL Ingredient Name Basis of Stren DROPERIDOL (UNII: 0590F0KOOR) Ingredient Name LACTIC ACID (UNII: 3X04XA5AT) Impredient Name Packaging Marketing Start 1 NDC:0143-9514- 25 in 1 CARTON 2 2 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination	droperidol injection, solution								
Route of Administration INTRAMUSCULAR, INTRAVENOUS Active Ingredient/Active Moiety Basis of Stren Ingredient Name Basis of Stren DROPERIDOL (UNII: O9U0F09D5X) (DROPERIDOL - UNII:O9U0F09D5X) DROPERIDOL Inactive Ingredients Ingredient Name Matter (UNII: 059QF0KOOR) Ingredient Name MATER (UNII: 059QF0KOOR) Ingredient Name MATER (UNII: 059QF0KOOR) Ingredient Name Matter (UNII: 059QF0KOOR) Ingredient Name Ingredient Name Ingredient Name WATER (UNII: 059QF0KOOR) Ingredient Name Ingredient Name									
Active Ingredient/Active Moiety Ingredient Name Basis of Stren DROPERIDOL (UNII: 09U0F09D5X) (DROPERIDOL - UNII:09U0F09D5X) DROPERIDOL Inactive Ingredients Ingredient Name WATER (UNII: 059QF0KO0R) LACTIC ACID (UNII: 33X04XA5AT) Packaging # Item Code Package Description Marketing Start 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination Product Marketing Information	e) NDC:0143-9514								
Ingredient Name Basis of Stren DROPERIDOL (UNII: O9U0F09D5X) (DROPERIDOL - UNII:O9U0F09D5X) DROPERIDOL Inactive Ingredients Ingredient Name WATER (UNII: 059QF0K00R) Imgredient Name LACTIC ACID (UNII: 33X04XA5AT) Imgredient Name # Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 01 25 in 1 CARTON 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product									
DROPERIDOL (UNII: O9U0F09D5X) (DROPERIDOL - UNII:O9U0F09D5X) DROPERIDOL INACTIVE INGREDIENTS INGREDIENTER (UNII: 059QF0K00R) LACTIC ACID (UNII: 33X04XA5AT) Packaging I tem Code Package Description Marketing Start Date I NDC:0143-9514- 25 in 1 CARTON 06/01/2022 I NDC:0143-9514- 25 in 1 CARTON 06/01/2022 I NDC:0143-9514- 25 in 1 VIAL; Type 0: Not a Combination Product Marketing Application Number or Monograph Marketing Start									
Inactive Ingredients Ingredient Name WATER (UNII: 059QF0K00R) LACTIC ACID (UNII: 33X04XA5AT) Packaging # Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 2 mL in 1 VIAL; Type 0: Not a Combination Product Marketing Information Marketing Application Number or Monograph Marketing Start	Basis of Strength Strength								
Ingredient Name Ingredient Name <th colspan="9"></th>									
WATER (UNII: 059QF0K00R) LACTIC ACID (UNII: 33X04XA5AT) Marketing Start Date Marketing Start Date # Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product Image: Colspan="4">Marketing Start Date	Strength								
INDC: 0143-9514- 25 in 1 CARTON Marketing Start Date NDC: 0143-9514- 25 25 in 1 CARTON 06/01/2022 NDC: 0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product Image: Colspan="3">Image: Colspan="3" Image: Colspan="3">Image: Colspan="3" Image: Colspa="3" Image: Colspan="3" Image: Colspan="3" Image: Col	Stiength								
# Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product ✓ Marketing Information Marketing									
# Item Code Package Description Marketing Start Date 1 NDC:0143-9514- 25 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product ✓ Marketing Information Marketing									
# Item Code Package Description Date 1 NDC:0143-9514- 25 25 in 1 CARTON 06/01/2022 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product Image: Comparison of the second se									
25 25 IN 1 CARTON 00/01/2022 1 NDC:0143-9514- 01 2 mL in 1 VIAL; Type 0: Not a Combination Product Image: Comparison of Carton Marketing Information Marketing Application Number or Monograph Marketing Start	Marketing End Date								
01 Product Marketing Information Marketing Application Number or Monograph									
Marketing Application Number or Monograph Marketing Start									
Marketing Application Number or Monograph Marketing Start									
	Marketing Information								
	Marketing End Date								
ANDA ANDA208197 06/01/2022									

Labeler - Hikma Pharmaceuticals USA Inc. (001230762)

Establishment							
Name	Address	ID/FEI	Business Operations				
HIKMA FARMACEUTICA (PORTUGAL), S.A		452742943	analysis(0143-9515, 0143-9514) , label(0143-9515, 0143-9514) , manufacture(0143-9515, 0143-9514) , pack(0143-9515, 0143-9514)				

Revised: 6/2022

Hikma Pharmaceuticals USA Inc.